Sarcoma  >>  Votrient (pazopanib)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Votrient (pazopanib) / Novartis, BeiGene
PREDICT, NCT01995981 / 2013-003533-16: Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

Completed
N/A
22
Europe
Pazopanib, Votrient
Radboud University Medical Center, GlaxoSmithKline
Sarcoma, Soft Tissue
11/17
11/17

Download Options